News & Updates
Showing Pharmacy articles
Showing
Dabrafenib plus trametinib boasts high pathological response for stage III melanoma
Pathological response rates are high for neoadjuvant dabrafenib plus trametinib among patients with stage III melanoma, but recurrence-free survival (RFS) rates are low, reports a study.
Dabrafenib plus trametinib boasts high pathological response for stage III melanoma
12 Aug 2024
First-line nivolumab-ipilimumab improves life quality, eases symptoms in metastatic CRC
First-line treatment with nivolumab (NIVO) in combination with ipilimumab (IPI) results in better health-related quality of life (HRQOL) and fewer symptoms, when compared with chemotherapy, in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), as shown in the CheckMate 8HW study presented at ESMO GI 2024.
First-line nivolumab-ipilimumab improves life quality, eases symptoms in metastatic CRC
12 Aug 2024
SGLT2i‒GLP1ra combo reduces risk of heart failure, mortality
Combination therapy with sodium-glucose transporter inhibitors (SGLT2i) and glucagon-like peptide receptor agonists (GLP1ra) prevents heart failure and improves long-term survival in a real-world population as compared with SGLT2i or GLP1ra monotherapy, according to a study.